AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ribonuclease inhibitor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P13489

UPID:

RINI_HUMAN

Alternative names:

Placental ribonuclease inhibitor; Ribonuclease/angiogenin inhibitor 1

Alternative UPACC:

P13489; Q8IZK8; Q96FD7; Q9BQ80; Q9UDK6

Background:

The Ribonuclease inhibitor, known as Placental ribonuclease inhibitor or Ribonuclease/angiogenin inhibitor 1, plays a crucial role in cellular mechanisms. It inhibits enzymes such as RNASE1, RNASE2, and ANG, which are vital for RNA metabolism. This protein's ability to regulate these enzymes underscores its importance in maintaining cellular homeostasis and protecting RNA integrity.

Therapeutic significance:

Understanding the role of Ribonuclease inhibitor could open doors to potential therapeutic strategies. Its involvement in inhibiting key enzymes suggests a protective mechanism that could be leveraged in diseases where RNA stability and integrity are compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.